Advertisement

Arcturus Therapeutics Holdings Inc. ARCT

Set alert

Price alert · ARCT

All alert types
11.03 USD -1.12 -9.22%

At close · Oct 30

10.51 -0.52 -4.67%

After hours · Oct 30, 6:12 PM ET

Bid
11.00 × 2
Ask
11.01 × 2
10.58 Day range 11.93
5.53 52-week range 16.93
YTD
+79.93%
1 year
+14.54%
Open
11.81
Prev close
12.15
Mkt cap
313.51M
Vol
1.85M
Avg vol
967.36K
EPS
-3.33
P/E
0.00
Div yield
0.00%
More statistics
Low
10.58
High
11.93
Forward P/E
-7.41
Beta
2.64
Short ratio
9.41
Inst. own
90.16%
Dividend
0.00
Ex-div date
50-d avg
18.22
200-d avg
24.44
1y target
79.47

1D chart

Chart tools
Interval

Signals (51)
NameTimeAgo
RSI: Overbought4:00 PM1 day ago
RSI: Overbought3:57 PM1 day ago
MACD: Sell Signal3:53 PM1 day ago
MACD: Buy Signal3:46 PM1 day ago
RSI: Overbought3:45 PM1 day ago
MACD: Sell Signal3:43 PM1 day ago
RSI: Overbought3:42 PM1 day ago
RSI: Overbought3:34 PM1 day ago
RSI: Overbought3:28 PM1 day ago
RSI: Overbought3:23 PM1 day ago
SMA: Bullish3:05 PM1 day ago
SMA: Bearish3:02 PM1 day ago
SMA: Bullish3:01 PM1 day ago
SMA: Bearish2:48 PM1 day ago
SMA: Bullish2:44 PM1 day ago
MACD: Buy Signal2:39 PM1 day ago
MACD: Sell Signal2:36 PM1 day ago
MACD: Buy Signal2:30 PM1 day ago
MACD: Sell Signal2:15 PM1 day ago
SMA: Bearish2:11 PM1 day ago
MACD: Buy Signal1:43 PM2 days ago
RSI: Oversold1:41 PM2 days ago
MACD: Sell Signal1:26 PM2 days ago
RSI: Oversold1:26 PM2 days ago
MACD: Buy Signal1:02 PM2 days ago
RSI: Oversold12:52 PM2 days ago
RSI: Oversold12:49 PM2 days ago
MACD: Sell Signal12:41 PM2 days ago
MACD: Buy Signal12:36 PM2 days ago
MACD: Sell Signal12:35 PM2 days ago
SMA: Bearish12:34 PM2 days ago
SMA: Bullish12:32 PM2 days ago
SMA: Bullish12:16 PM2 days ago
MACD: Buy Signal12:16 PM2 days ago
MACD: Sell Signal12:08 PM2 days ago
SMA: Bullish11:56 AM2 days ago
MACD: Buy Signal11:56 AM2 days ago
SMA: Bearish11:40 AM2 days ago
SMA: Bearish11:36 AM2 days ago
MACD: Sell Signal11:21 AM2 days ago
RSI: Overbought11:11 AM2 days ago
SMA: Bullish10:55 AM2 days ago
SMA: Bearish10:51 AM2 days ago
SMA: Bullish10:44 AM2 days ago
MACD: Buy Signal10:27 AM2 days ago
MACD: Sell Signal10:24 AM2 days ago
MACD: Buy Signal10:23 AM2 days ago
RSI: Oversold10:23 AM2 days ago
RSI: Oversold10:15 AM2 days ago
RSI: Oversold10:02 AM2 days ago
RSI: Oversold9:55 AM2 days ago

Key statistics

Market cap
447.75M
Enterprise value
211.56M
Trailing P/E
0.00
Forward P/E
-7.41
PEG ratio
0.00
Price / sales
2.79
Price / book
1.71
EPS (TTM)
-2.33
Beta
2.64
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-39.05%
Revenue (TTM)
160.40M
Revenue growth
-7.70%
Free cash flow
-40.26M
Total cash
237.18M
Total debt
29.42M
Return on equity
-23.12%
Shares outstanding
27.09M
Short % of float
25.29%
50-day average
18.22
200-day average
24.44

Analyst view

Consensus: strong buy

Strong buy
Price target (mean) 79.47 +620.5% upside
Target (low)
44.00
Target (mean)
79.47
Target (high)
140.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
  • Strong buy3
  • Buy7
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Consensus EPS estimate 0.22333.

Earnings history

Financials — quick view

All financials
ARCT Revenue — quarterly 2.96M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ARCT Net income — quarterly -23.79M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
ARCT EPS — quarterly -0.84
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

ARCT recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 7, 2024Sep 1, 2024-0.70-0.26+0.44+62.86%
Aug 5, 2024Jun 1, 2024-1.85-0.64+1.21+65.41%
May 8, 2024Mar 1, 2024-1.17-1.00+0.17+14.53%
Mar 7, 2024Dec 1, 2023-1.69-0.32+1.37+81.07%
Nov 14, 2023Sep 1, 2023-1.79-0.61+1.18+65.92%
Aug 7, 2023Jun 1, 20230.09-1.98-2.07-2,300.00%

Upgrades / downgrades

ARCT analyst upgrades and downgrades
DateFirmActionFromTo
Dec 17, 2024HC Wainwright & Co.reitBuyBuy
Dec 16, 2024Cantor FitzgeraldreitOverweightOverweight
Nov 8, 2024HC Wainwright & Co.reitBuyBuy
Aug 12, 2024Leerink Partnersinit—Outperform
Aug 8, 2024HC Wainwright & Co.mainBuyBuy
Aug 6, 2024Cantor Fitzgeraldreit—Overweight

About Arcturus Therapeutics Holdings Inc.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ARCT — it syncs with the Stock Master app.

Insider holders

ARCT insider holders
InsiderRelationLatest transactionDateShares held
BARLOW JAMES F.DirectorConversion of Exercise of derivative securityJun 13, 202413,131
CHIVUKULA PADMANABHChief Operating OfficerSaleOct 14, 2024435,334
FARRELL PETER CRAIGDirectorConversion of Exercise of derivative securityJun 13, 202498,696
HOLMES EDWARD W.DirectorConversion of Exercise of derivative securityJun 13, 20243,131
KUMMERFELD KEITH COfficerSaleJul 13, 2023950
MARANTZ JING L.DirectorConversion of Exercise of derivative securityJun 13, 20243,131

Institution ownership

ARCT institution ownership
Holder% heldSharesValueReported
Federated Hermes, Inc.17.33%4,694,06077.59MSep 29, 2024
Blackrock Inc.10.90%2,952,01348.80MSep 29, 2024
Nikko Asset Management Americas, Inc.8.55%2,315,29438.27MSep 29, 2024
Sumitomo Mitsui Trust Holdings, Inc.8.40%2,275,71537.62MSep 29, 2024
ARK Investment Management, LLC7.76%2,101,03834.73MSep 29, 2024
Vanguard Group Inc5.82%1,576,92626.07MSep 29, 2024

Fund ownership

ARCT fund ownership
Holder% heldSharesValueReported
Federated Hermes Kaufmann Fund8.99%2,435,88040.27MJul 30, 2024
Federated Hermes Kaufmann Small Cap Fund8.11%2,198,02036.33MJul 30, 2024
ARK ETF Tr-ARK Genomic Revolution ETF7.53%2,038,67533.70MOct 30, 2024
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF2.77%749,64412.39MSep 29, 2024
Vanguard Total Stock Market Index Fund2.67%723,64011.96MSep 29, 2024
iShares Russell 2000 ETF2.19%593,7819.82MOct 30, 2024
Advertisement